Which vaccines are still effective against delta variants?

Recently, the Delta variant of the new coronavirus has received more and more attention.

A British study found that Delta seems to be about 60% higher than the already highly contagious Alpha variant (also known as B.

Data from the United Kingdom shows that in the past 7 days, new SARS-CoV-2 infections have increased by 31%

A recent analysis by PHE looked at the likelihood that people infected with the delta variant will need to be treated in the hospital

These are comparable to the vaccine effectiveness of Alpha variants for hospitalization

An analysis previously published by Public Health England (PHE) showed that compared with Alpha, one dose is 17% less effective in preventing symptomatic diseases caused by the Delta variant, but there is only a small difference after 2 doses

Compared with Alpha, one dose is 17% less effective in preventing symptomatic diseases caused by Delta variants, but there is only a small difference after 2 doses

The report has not yet been peer-reviewed and compares these percentages with protection against alpha variants or B.

A previous report indicated that if people only get the first dose of Pfizer-BioNTech or Oxford-AstraZeneca vaccine, the COVID-19 vaccine is less effective in protecting people from COVID-19 infection

Covaxin vaccine data

Covaxin vaccine dataCovaxin vaccine data

Currently, there is little data on how other COVID-19 vaccines combat delta variants

Neutralization against B.

Neutralization against B.

Covaxin is made from the entire SARS-CoV-2 virus, which has been chemically modified to prevent its replication

However, this study is small in scale and further research is needed to understand how effective the Covaxin COVID-19 vaccine is in preventing severe COVID-19 caused by delta variants in a real-world environment

Russian Satellite V Covid-19 Vaccine

Russian Satellite V Covid-19 VaccineRussian Satellite V Covid-19 Vaccine

Alexander Gintsburg, director of the Gamaleya Institute of Epidemiology and Microbiology in Russia, announced on Twitter that the Russian satellite V new crown vaccine can effectively combat all variants of the new crown virus

Until the data is made public, it is impossible to assess the validity of these claims about the Sputnik V vaccine

CoronaVac (CoronaVac)

Coxing New Crown Vaccine (CoronaVac) Coxing New Crown Vaccine (CoronaVac)

There are also few available data on the effectiveness of Coxing's new crown vaccine against delta variants
.
Reuters pointed out that earlier this week, Indonesia stated that more than 350 health care workers were infected with the new coronavirus Delta after being vaccinated by Kexing, raising concerns about the effectiveness of Kexing
.
According to the report, Badai Ismoyo, head of the Kudus District Health Office in Central Java, said: “Most employees are asymptomatic and self-isolate at home, but dozens of people have been hospitalized due to high fever and decreased blood oxygen saturation
.
”

"Most employees are asymptomatic and self-isolate at home, but dozens of people are hospitalized due to high fever and decreased blood oxygen saturation
.
" "Most employees are asymptomatic and self-isolate at home, but dozens of people have high fever and blood oxygen saturation.
Hospitalization due to a drop in degree
.
"

There are a large number of infections in this area, and experts believe that this is mainly caused by delta variants
.
In light of the Reuters report, it is clear that more research is needed to determine the extent to which CoronaVac can prevent severe COVID-19 caused by the delta variant
.

In light of the Reuters report, it is clear that more research is needed to determine the extent to which CoronaVac can prevent severe COVID-19 caused by the delta variant
.
In light of the Reuters report, it is clear that more research is needed to determine the extent to which CoronaVac can prevent severe COVID-19 caused by the delta variant
.

 

Reference materials:

References: References:

1. SARS-CoV-2 variant B.
   1.
   617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination, doi:  https://doi.
   org/10.
   1101/2021.
   05.
   04.
   442663
2. Neutralization against B.
   1.
   351 and B.
   1.
   617.
   2 with sera of COVID-19 recovered cases and vaccinees of BBV152, doi: https://doi.
   org/10.
   1101/2021.
   06.
   05.
   447177

SARS-CoV-2 variant B.
1.
617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination, doi:  https://doi.
org/10.
1101/2021.
05.
04.
442663

SARS-CoV-2 variant B.
1.
617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination, doi:  https://doi.
org/10.
1101/2021.
05.
04.
442663 SARS-CoV-2 variant B.
1.
617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination, doi:  https://doi.
org/10.
1101/2021.
05.
04.
442663 https://doi.
org/10.
1101/2021.
05.
04.
442663

Neutralization against B.
1.
351 and B.
1.
617.
2 with sera of COVID-19 recovered cases and vaccinees of BBV152, doi: https://doi.
org/10.
1101/2021.
06.
05.
447177

Neutralization against B.
1.
351 and B.
1.
617.
2 with sera of COVID-19 recovered cases and vaccinees of BBV152, doi: https://doi.
org/10.
1101/2021.
06.
05.
447177 Neutralization against B.
1.
351 and B.
1.
617.
2 with sera of COVID-19 recovered cases and vaccinees of BBV152, doi: https://doi.
org/10.
1101/2021.
06.
05.
447177

 

Leave a message here